Mortality in patients with Parkinson's disease treated by stimulation of the subthalamic nucleus

Authors

  • Michael W.M. Schüpbach MD,

    1. Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France
    Search for more papers by this author
  • Marie Laure Welter MD,

    1. Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France
    Search for more papers by this author
  • Anne Marie Bonnet MD,

    1. Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France
    Search for more papers by this author
  • Alexis Elbaz MD, PhD,

    1. National Institute of Health and Medical Research (INSERM) Unit 708 (former Unit 360), Hôpital de la Salpêtrière, Paris, France
    Search for more papers by this author
  • Brandon R. Grossardt MS,

    1. Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Search for more papers by this author
  • Valerie Mesnage MD,

    1. Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France
    Search for more papers by this author
  • Jean Luc Houeto MD,

    1. Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France
    Search for more papers by this author
  • David Maltête MD,

    1. Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France
    Search for more papers by this author
  • Luc Mallet MD, PhD,

    1. Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France
    Search for more papers by this author
  • Walter A. Rocca MD, MPH,

    1. Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    2. Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Search for more papers by this author
  • Alain Mallet PhD,

    1. Department of Biostatistics and Medical Information, Pitié-Salpêtrière Medical University, Paris, France
    Search for more papers by this author
  • Yves Agid MD, PhD

    Corresponding author
    1. Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France
    • Centre d'Investigation Clinique, Hôpital de la Salpêtrière, 47 boulevard de l'Hôpital, 75013 Paris, France
    Search for more papers by this author

Abstract

Subthalamic nucleus (STN) stimulation improves motor disability and quality of life in patients with advanced Parkinson's disease (PD). Short-term mortality is low, but little is known about long-term mortality. We assessed mortality and causes of death in 171 consecutive PD patients treated by STN stimulation. Surgery was performed after a median lagtime of 13 years from PD onset at a median age of 57 years. The median follow-up after surgery was 41 months. Sixteen patients died 8 to 83 months after neurosurgery. Poorer cognitive function was the only predictive factor for mortality (standardized mortality ratio = 2.9; 95% confidence interval [CI], 1.6–4.7; P < 0.0001). Based on a historical comparison of 118 operated patients with 39 nonoperated patients from a different population, survival among operated patients was not better (hazard ratio = 1.2; 95% CI, 0.7–2.1). © 2006 Movement Disorder Society

Ancillary